RedHill supports an independent medical education grant that includes a new two-part H Pylori Continuing Medical Education (CME) program developed by Medscape aimed at advancing clinical knowledge and improving patient outcomes pylori is classified by the World Health Organization (WHO) as a Group 1 carcinogen being the strongest known risk factor for gastric cancer[1] and a major risk factor for peptic ulcer disease[2] With almost half the global population infected by H its treatment represents a billion-dollar market opportunity[4] Listed by the American College of Gastroenterology (ACG) Clinical Guideline[5] as a first-line option low-dose rifabutin-based therapy designed to address H RALEIGH, N.C., May 2, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company") today announced its support of an independent medical education grant that includes a new two-part H developed by Medscape and designed to advance clinical knowledge and improve patient outcomes a livestreamed event entitled "Let's Get Social About H will take place on May 6 during a major gastroenterology meeting RedHill also announces that it will be attending Digestive Diseases Week (DDW) in San Diego and will be available at booth 5312 said: "We are proud to announce that RedHill is supporting a Medscape CME educational program to help meet the need for healthcare professional education on H RedHill believes in the critical need to effectively treat H pylori at the first attempt amid increasing global concern of rising antibiotic resistance particularly within the macrolide class of anti-infectives pylori is estimated to be carried by around 50% of the global population and it is the strongest known risk factor for gastric cancer and a major risk factor for peptic ulcer disease This CME program is targeted to help thousands of specialists by providing education on guideline-driven H designed to advance clinical knowledge and improve patient outcomes in H The 2-part Medscape CME program consists of: Overview: A 30-minute expert panel livestream (0.5 CME Credits) on Medscape's social media channels (YouTube The event will remain available on-demand post-livestream to support those gastroenterology professionals unable to attend the live event Part 2: Expert Roundtable: Overcoming Challenges in H pylori Diagnosis and TreatmentFaculty: Colin Howden MPHDate/Time: June 2025 (TBD)Overview: A 30-minute interactive case-based online discussion (0.5 CME Credits) in order to help clinicians translate key guideline updates into clinical practice pylori infection affects around 50% of the global adult population and is classified as a Group 1 carcinogen and the strongest known risk factor for gastric cancer (causing between 70% to 90% of cases)[6] and a major risk factor for peptic ulcer disease (causing 90% of cases)[7] gastroenterologists and is listed by ACG Clinical Guideline as an empiric first-line option Talicia is also launched in the United Arab Emirates (UAE) and the Company recently announced its plan to submit a Marketing Authorisation Application (MAA) for Talicia in the UK which if approved may be accepted by some additional countries as a reference for their own approval processes which could expedite ongoing discussions with prospective territorial commercialization partners for Talicia pylori          H pylori is a bacterial infection that affects approximately 35% of the U.S with an estimated two million patients treated annually which is classified by the World Health Organization (WHO) as a Group 1 carcinogen It remains the strongest known risk factor for gastric cancer and a major risk factor for peptic ulcer disease and gastric mucosa-associated lymphoid tissue (MALT) lymphoma[9] More than 27,000 Americans are diagnosed with gastric cancer annually[10] pylori is becoming increasingly difficult with current therapies failing in approximately 25-40% of patients who remain H pylori-positive due to high resistance of H pylori to antibiotics – especially clarithromycin – which is still commonly used in standard combination therapies[11] About TaliciaApproved by the FDA for the treatment of H pylori infection in adults in November 2019 all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole) market exclusivity under its Qualified Infectious Disease Product (QIDP) designation and is also covered by U.S patents which extend patent protection until 2034 with additional patents and applications pending and granted in various territories worldwide  Talicia is also approved by the United Arab Emirates (UAE) Ministry of Health and was launched there by Ghassan Aboud Group (GAG) in August 2024 TALICIA: INDICATION AND IMPORTANT SAFETY INFORMATIONTalicia is a three-drug combination of omeprazole indicated for the treatment of Helicobacter pylori infection in adults.         To reduce the development of drug-resistant bacteria and maintain the effectiveness of Talicia and other antibacterial drugs Talicia should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.  About RedHill Biopharma   RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal drug Talicia, for the treatment of Helicobacter pylori (H with submission planned for marketing authorization in other territories. RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640) orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer targeting multiple indications with U.S Government and academic collaborations for development for radiation and chemical exposure indications such as Gastrointestinal-Acute Radiation Syndrome (GI-ARS) a Phase 2 study in prostate cancer in combination with Bayer's darolutamide and a Phase 2/3 program for hospitalized COVID-19 patients; (ii) RHB-204 combination antibiotic therapy with a planned Phase 2 study for Crohn's disease and Phase 3-stage for pulmonary nontuberculous mycobacterial (NTM) disease; (iii) RHB-104 with positive results from a first Phase 3 study for Crohn's disease; (iv) RHB-107 (upamostat) host-directed, serine protease inhibitor with potential for pandemic preparedness is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19 and is also targeting multiple other cancer and inflammatory gastrointestinal diseases; and (v) RHB-102 with potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside North America More information about the Company is available at: www.redhillbio.com / twitter.com/RedHillBio.  This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties many of which are beyond the Company's control and cannot be predicted or quantified actual results may differ materially from those expressed or implied by such forward-looking statements without limitation: market and other conditions; the Company's ability to regain and maintain compliance with the Nasdaq Capital Market's listing requirements; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk of current uncertainty regarding U.S government research and development funding and that the U.S such studies and results may not be sufficient for regulatory applications including emergency use or marketing applications and that additional studies may be required; the risk of market and other conditions and that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation progress and results of the Company's research and other therapeutic candidate development efforts and the timing of other regulatory filings approvals and feedback; (iv) the manufacturing and market acceptance of the Company's therapeutic candidates and Talicia®; (v) the Company's ability to successfully commercialize and promote Talicia®; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company's expenses capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company's industry; and (xv) the hiring and employment commencement date of executive managers More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC) including the Company's Annual Report on Form 20-F filed with the SEC on April 10 All forward-looking statements included in this press release are made only as of the date of this press release The Company assumes no obligation to update any written or oral forward-looking statement future events or otherwise unless required by law Company contact:Adi FrishChief Corporate & Business Development OfficerRedHill Biopharma+972-54-6543-112[email protected] Logo: https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg (Nasdaq: RDHL) ("RedHill" or the "Company") today announced that the Company received.. Medical Pharmaceuticals Biotechnology Education Health Care & Hospitals Do not sell or share my personal information: Jersey Bulls' only losses have come at home to Redhill and fellow title chasers Whyteleafe Redhill knocked Jersey Bulls off the top of Combined Counties Premier South as the islanders lost 2-1 at home to their title rivals Having drawn 1-1 in Surrey last week the pair met at Springfield knowing a win for the islanders would put them three points clear with two games to play But two goals in as many second-half minutes saw the English side become just the second team to beat the islanders in the league this season Bulls had the better of the opening exchanges as Lorne Bickley had a penalty claim turned down before Adam McKay and Toby Ritzema headed wide from Miguel Carvalho crosses But the hosts went ahead in the 28th minute as Adam Trotter finished well after Joe Kilshaw had broken up the play Bulls could have gone into the break 2-0 up but Bickley hit the bar shortly after the opener It was a miss they would regret as Redhill levelled when Timmy Obisanya poked the ball home from a goalmouth scramble following a floated 57th-minute free kick from the edge of the box And almost straight away Redhill were in front when substitute Elliott York blasted in from 12 yards after Euan van der Vliet had saved Nathan Hogan's shot James Queree had a header palmed wide while Kurtis Guthrie had a penalty appeal waved away inside the final 10 minutes as the island side pushed unsuccessfully for an equaliser "We pressed the self-destruct button for five minutes and it cost us three points which would have probably sealed it so disappointed," Bulls manager Elliot Powell told BBC Radio Jersey The result leaves Redhill three points clear of Bulls with a game against mid-table Guildford City to play Jersey Bulls would likely still win the title should they win their final two games thanks to their goal difference They travel to mid-table Abbey Rangers on Tuesday night before hosting relegation-threatened Sandhurst Town at Springfield next week but will Yamal build legacy to rival Messi 'Calamity keeper' or 'human wall' - which Donnarumma will Arsenal face Who will qualify for the Champions League as Forest draw at Palace The final series of Man Like Mobeen has arrived John Simm stars in the provocative 90s drama Warm-hearted comedy with Ben Miller and Sally Phillips Follow two ambitious river restoration projects Who has made Troy's Premier League team of the week Is the risk that Mercedes took with Antonelli paying off Trailblazer Zhao set to take snooker to 'another level' in China Zhao beats Williams in historic final - highlights VideoZhao beats Williams in historic final - highlights Alexander-Arnold leaves as modern Liverpool great - but fans will feel hurt 'Scheffler and DeChambeau wins further raise US PGA excitement levels' Match-fixing scandal to Crucible champion - fall and rise of Zhao 'We need to take a look at ourselves' - Arsenal stalling at wrong time Europa League 'papering over cracks' for Man Utd - Rooney VideoEuropa League 'papering over cracks' for Man Utd - Rooney Ask Me Anything the new BBC Sport service designed to serve you Bayern's 'James Bond' - how Kane clinched his first trophy Nine bolters with a shot of making the Lions squad How 'absolutely outstanding' Palmer 'destroyed' Liverpool VideoHow 'absolutely outstanding' Palmer 'destroyed' Liverpool Solskjaer on Besiktas Saints 'punch' favourites Leinster in game for the ages VideoVardy the best £1m ever spent - Shearer Poppy's tears Elton John & Happy Gilmore - McIlroy on Jimmy Fallon show Copyright © 2025 BBC. The BBC is not responsible for the content of external sites. Read about our approach to external linking. Redhill and Jersey Bulls were only separated by goal difference before kick-off Jersey Bulls were denied the chance to go three points clear at the top of Combined Counties Premier South after drawing 1-1 at second-placed Redhill in a fiery encounter The hosts played the second half with 10 men and levelled moments after Luke Campbell had put the islanders in front late on In a tight first-half Miguel Carvalho fired into the side netting after 26 minutes for Bulls before Euan van der Vliet pulled off a superb save soon after as Redhill tried to go ahead Tensions had been strained for much of the first half and threatened to boil over shortly before half-time as Bulls striker Lorne Bickley was brought down and players from both sides came together The hosts had early substitute Sean Swift sent off for a second booking in the fourth of 17 minutes of first-half stoppage time after a foul on Fraser Barlow before the islanders had an effort deflected wide soon after With the extra man Bulls created more chances as Luke Watson had a header saved by Luke Roberts before the Redhill keeper superbly kept out a Joe Kilshaw effort with seven minutes to go But two minutes later an unmarked Campbell put the islanders in front with a back post header from a corner Seb Tauta-Caballero then equalised in the first minute of stoppage time as he reacted quickest to tap in after Van der Vliet could not hold a Redhill shot The result leaves the two sides tied on 90 points although Bulls have a game in hand with third-placed Whyteleafe four points off them Redhill travel to Jersey in a week's time for a game which could prove decisive in where the title will end up because obviously a point in terms of the league table is a really positive result," Jersey Bulls manager Elliot Powell told BBC Radio Jersey "But it's just a bit of a sickener not to have won it "I thought we did the running in the second half obviously they're down to 10 and they were going to tire but when we went 1-0 up it was disappointing that we haven't seen that game out "It was a great save from Euan and it's just fallen straight back to his feet and he's slammed it in but in the grand scheme of things it's a decent point and sets us up well for next week." Jersey Bulls had topped the table on goal difference Jersey Bulls have failed in their appeal against a points deduction that cost them the Combined Counties Premier South title The islanders were docked three points after played a suspended player in their 4-0 win over Tooting and Mitcham in late March The club had appealed to the Football Association (FA) to try and overturn the points deduction The Combined Counties League is assessing a number of other cases of ineligible players, and as yet no dates for the play-offs have been announced. As it stands Bulls will drop to third place in the league table although it is understood rivals Redhill are also facing a similar charge and would fall to third with Whyteleafe winning the title Jersey Bulls end season with win after title disappointment Jersey Bulls title hopes in balance after points deduction Play-offs postponed as Bulls appeal points deduction In a statement Jersey Bulls say the FA's judgement read: League Rule 6.9 directs that the Club shall have any points gained from the match in question deducted "The Appeal Board concluded that there were no exceptional circumstances in this case and that the process that had been followed was fair." The case centred on midfielder Toby Ritzema who received 10 bookings - one coming in the FA Vase Bulls mistakenly counted that booking as counting towards the 10 and therefore he served a two-match ban in the league when he did not need to He subsequently passed the 10-booking threshold in league games and should have been suspended for the Tooting and Mitcham win on 29 March Redhill residents outside Reigate & Banstead Borough Council opposing plans to build in the town centre Plans to build the Redhill’s tallest ever high rise have been refused by Reigate & Banstead Borough Council a result that left residents cheering the “amazing” decision together with its development partners Kier who are currently building high rise blocks at Guildford Station as part of a £6 million refurbishment plan for the town’s train station They argued the project would transform Redhill Railway Station which hadn’t had significant investment since the 1980s Instead councillors at the Planning Committee on Wednesday sided with the near 2,000  objectors who said the huge housing scheme would change the character of Redhill forever – and set the unwanted precedent for more tall buildings to come where councillors voted 11 to two with two abstentions to refuse the application was Jan Sharman of the East Redhill Residents’ Association Residents were pleased to hear of the Planning Committee’s decision it was a shock actually even though we knew we had a strong case for it to be turned down it was actually the highest building they would ever build in Redhill.” The plans called for 255 one-and-two bedroom apartments but the committee heard the town was already over stocked in that department – and not a single one  would  have been made affordable the committee heard money would be ploughed into refurbishing Redhill station Jan said: “Some of the flats had no daylight It would just have been making us into a mini Croydon and we’re not Croydon.” She added: “We know something has to be done on that site it’s a very important brownfield site but (the plan) was mediocre “It was turned down on density and height and lack of affordable housing A CGI of the proposed 15 and 14-storey tower blocks included in the proposal “The height was just astronomical and the community had to put a stop to it.” The scheme had been recommended for approval but instead served to reawaken the East Redhill Residents’ Association first formed about 30 years ago to twice fight off county plans for an incinerator whose efforts helped generate others to take a stand The developers had hoped to create the homes across two buildings ranging from 10-15 storeys and seven to 14 storeys respectively Commuter parking would have fallen by 10 per cent had they been approved but the developers argued a similar sized scheme at the edge of the town would have a far greater impact on traffic and create thousands of extra car journeys Speaking in favour of the bid was Robin Dobson He told the meeting the income from the 255 homes would result in a £6 million refurbishment of Redhill station – which has had no investment in more than 40 years Furthermore there was a take-it-or-leave it £2 million grant  on offer from TfL (Transport for London) dependent on the plans getting a green light He said: “The scheme would transform the station and create a new neighbourhood giving young people the opportunity to remain in the town where they grew up and want to continue to live “This application is the culmination of many years of hard work He added: “It supports the regeneration of the town centre and the gateway to Redhill This is the main way we can deliver the scale of change and investment in the station “Having a great station and landmark into the town should not be underestimated in Guildford – very similar  opportunities that we have delivered and delivered business investment and local prosperity The new station would be a source of pride.” The proposal for the Solum development in Guildford was also  rejected by the borough council Ultimately Reigate & Banstead councillors refused the Redhill station development by virtue of its height saying it would fail to make a positive contribution to the character and appearance the area and cause harm to the town’s conservation areas they said particularly in  the absence of affordable housing Robin Dobson of Network Rail argued for the proposal saying: “Having a great station and landmark into the town should not be underestimated in Guildford – very similar opportunities that we have delivered Is it just me or is this – as far as Guildford is concerned – utter nonsense Δdocument.getElementById( "ak_js_1" ).setAttribute( "value" See: Comment - We Need Change But Not the Kind Being Imposed By Labour’s ‘Devolution’